Sign in
Taking peoplePhase 2

Efficacy and Safety of SR1375 in Adult Patients With CAP

Key facts

Who runs it
Shanghai SIMR Biotechnology Co., Ltd.
Where
China29 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
240 people, planned
Started
10 Sept 2024
Planned end
30 Oct 2025
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • SR1375 capsule 3mg+regular treatments
  • SR1375 capsule 1mg+regular treatments
  • SR1375 capsule 0.3mg+regular treatments
  • Placebo capsule+regular treatments
Record updated
9 July 2025

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • The subject or their legally acceptable representative (LAR) has voluntarily signed the informed consent form (ICF) prior to any study-related procedures, and the subject is willing and able to comply with all study requirements, restrictions, and procedures. If consent is provided by an LAR for a subject with limited or no capacity to consent, re-consenting may be performed if the subject regains capacity
  • Aged 18 to 85 years
  • Diagnosis of CAP
  • Prior to screening, the subject has been receiving standard-of-care treatment for pneumonia in a medical institution, including at least 3 days of intravenous (IV) anti-infective therapy, with no clinical improvement
  • Chest CT showing multi-lobar infiltrates, and for subjects not receiving invasive mechanical ventilation, an oxygenation index (PaO2/FiO2 ratio) between 100 and 300 mmHg
  • Expected to require continued hospitalization for at least 7 days from the time of signing the ICF
  • Baseline NIAID-OS 8-point scale score of 5 points and transcutaneous oxygen saturation ≤ 93% without oxygen inhalation, 6 points or 7points. (5 points refer to hospitalization with oxygen therapy; 6 points refer to hospitalization with high flow oxygen therapy or non-invasive mechanical ventilation. 7 points refer to hospitalization with invasive mechanical ventilation).High oxygen flow refers to ≥ 4 L/min.)
  • With ≥ 1 high risk factors including chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, type 2 diabetes, chronic kidney disease, coronary heart disease, age ≥ 65 years, moderate obesity (body mass index>32.5kg/m2), etc
  • Participants of women of childbearing potential(WOCBP) and male participants with WOCBP partners must agree to use one or more effective contraceptive methods during the treatment period and until 90 days after the last administration

Who cannot take part

  • Patients who are currently receiving or are expected to require ECMO treatment within 24 hours
  • History of unstable angina or acute myocardial infarction within 3 months prior to screening, or stroke within 4 weeks prior to screening
  • Received chemotherapy and/or immunotherapy for a malignant tumor within 4 weeks prior to randomization, or are planned to receive such treatment during the study period; presence of a hematological malignancy not in complete remission; or a lung tumor with concurrent obstructive pneumonia
  • Presence of any concomitant disease that is expected to result in death within 12 weeks after randomization
  • Prior use of JAK inhibitors (e.g., Baricitinib), interleukin receptor inhibitors (e.g., Tocilizumab), or any investigational drug in another clinical trial, where the last dose was administered less than 5 half-lives before the first dose of the study drug in this trial
  • Presence of active tuberculosis (TB) or severe asthma
  • Presence of any severe systemic disease or clinical condition that, in the investigator's judgment, makes the subject unsuitable for participation in this study
  • ALT) or AST > 3 times the upper limit of normal (ULN)
  • eGFR < 30 mL/min/1.73 m² (calculated using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula); however, patients undergoing dialysis may be included upon the investigator's assessment of their suitability for the trial
  • Female subjects who are pregnant, lactating, or have a positive serum β-HCG pregnancy test
  • Presence of clinically significant abnormalities on ECG that may seriously affect subject safety, e.g., QTcF > 480 ms

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a phase 2 study to evaluate the efficacy and safety of SR1375 in hospitalized adult patients with CAP. Patients will receive SR1375 or placebo for 8 weeks. The study duration for each patient is up to 10 weeks.

The 4 groups in the trial

  • SR1375 capsule 3mgTreatment being tested

    SR1375 capsule 3mg quaque die(QD) orally with CAP regular treatments for 8 weeks

    Treatment: SR1375 capsule 3mg+regular treatments

  • SR1375 capsule 1mgTreatment being tested

    SR1375 capsule 1mg QD orally with CAP regular treatments for 8 weeks

    Treatment: SR1375 capsule 1mg+regular treatments

  • SR1375 capsule 0.3mgTreatment being tested

    SR1375 capsule 0.3mg QD orally with CAP regular treatments for 8 weeks

    Treatment: SR1375 capsule 0.3mg+regular treatments

  • placebo capsulePlacebo, for comparison

    Placebo capsule QD orally with CAP regular treatments for 8 weeks

    Treatment: Placebo capsule+regular treatments

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SR1375 in Hospitalized Adult Patients With Community-acquired Pneumonia
Criteria questions
Built from NCT06577558, who can take part
Record updated
9 July 2025